Actionable circadian and insomnia interventions with timing emphasis.
Bright light therapy
Goal advance (DSWPD/late sleep): Morning light 30–60 min at 2,500–10,000 lux; avoid evening blue light [3], [8], [4], [7].
Goal delay (ASWPD/early awakenings): Evening light 30–60 min; limit early-morning light with sunglasses if outdoors [3], [7].
Device light hygiene: blue-light filters, dim lights 2–3 h before target bedtime; maximize post-wake light.
Cautions: migraine, bipolar spectrum (monitor activation), retinal disease—coordinate with ophthalmology if needed [3].
Melatonin and agonists
Advance timing: 0.3–1 mg 4–8 h before habitual bedtime (≈5–6 h before DLMO) for DSWPD; higher doses do not increase phase shift and may cause sleepiness [8], [4], [5].
Delay timing: low-dose morning melatonin for ASWPD; avoid evening dosing in advanced phase.
Agonists: consider ramelteon or melatonin agonists when insomnia plus CRSWD or mood disorders are present [6].
Safety: daytime sedation, interaction with anticoagulants; standardize brand/formulation to reduce variability.
CBT‑I essentials
Sleep restriction to consolidate sleep; titrate by weekly sleep efficiency.
Stimulus control: bed only for sleep; leave bed if awake >15–20 min.
Cognitive work: reframe catastrophic sleep beliefs; paradoxical intention for sleep effort.
Relapse plan: protect wake time, travel/shift protocols, and light exposure anchors [7].
Shift work & jet lag
Shift work: phase-directional light blocks at work vs commute; strategic naps; caffeine early in shift; melatonin for daytime sleep facilitation as appropriate [3], [7].
Jet lag: eastward—advance pre-trip with earlier sleep, morning destination light and pre-sleep melatonin; westward—delay schedule with evening light at destination [3], [11].
Protect circadian cues: consistent meals, exercise timing aligned to target phase.
Pharmacologic insomnia options
Network meta-analysis: differing short- vs long-term efficacy and harms; tailor to age/comorbidity and minimize duration [9].
Avoid routine antipsychotics or strong anticholinergics for insomnia; monitor for falls, cognitive effects in older adults.
Always pair with circadian measures to reduce dose and prevent dependence.
When to refer
Refractory DSWPD/ASWPD requiring chronotherapy or DLMO measurement.
Complex comorbidity (bipolar disorder, severe ocular disease).
Suspected comorbid sleep apnea, RLS/PLMD, or parasomnias complicating insomnia.